pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·3h ago·1 min read
save

NIH to restrict Pathways to Independence grants to U.S. citizens and permanent residents

Aug 7, 2026·read at STAT ↗RegulatoryNegative

The National Institutes of Health announced plans to limit eligibility for its “Pathways to Independence” award to U.S. citizens, permanent residents, and non‑citizen nationals. The change would bar international researchers on visas from applying for the program.

The Pathways to Independence award, also known as the K99/R00, provides two years of postdoctoral funding followed by three years of support for establishing an independent laboratory. It has been one of the few federal mechanisms that allowed non‑U.S. scientists to secure stable funding while building a career in American biomedical research.

Experts warn that removing this option could make it harder for promising scholars on visas to find a foothold in the United States, potentially weakening the pipeline of talent that fuels drug discovery and academic innovation.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: NIH plans to block international researchers on visas from accessing key funding avenue”

read at STAT ↗
469 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
National Institutes of Health2ELI LILLY COLILLY
drugs
Obesity
topics
CRISPR/Cas9Obesity

related stories

  • 1d agoSTAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AISTAT
  • 2d agoSTAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safetySTAT
  • 2d agoSTAT+: Moderna launches early trial of Ebola mRNA vaccineSTAT
  • 2d agoSTAT+: Senate inquiry suggests Trump administration softened kratom and tobacco policies in quid pro quoSTAT
  • 2d agoSTAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis findsSTAT